BIA Committee Summit 2018

This event is now full - please email Dannielle Sinclair

The BIA’s eight advisory committees are crucial mechanisms for highlighting the most relevant issues facing bioscience companies. We are delighted to invite you to the fourth Committee Summit where our committees will present and update on their 2017 objectives and explain key issues for 2018. Steve Bates OBE, Chief Executive Officer, BIA will provide an update on BIA activities and plans.

We welcome existing committee members and the wider BIA community to join us at Simmons and Simmons in London.

Registering for more than one committee meeting
You can only register for one committee meeting online. To register for any additional committee meetings,  please email Dannielle Sinclair.

Thursday 22 February 2018

Simmons and Simmons
1 Ropemaker St


08:30 - 09:00      Registration, coffee and networking

09:00 -11:00       Meetings of the following BIA Advisory Committees

  • Cell and Gene Therapy
  • Finance and Tax
  • Science and Innovation
  • At this time there is also the opportunity to join a BIA-led brainstorming session on the needs of the sector in relation to Talent, Skills and People

11:00 -12:30 Plenary session including BIA update and Review of 2017 and Plans for 2018 from Advisory Committee Chairs

12:30 -13:30 Lunch and networking

13:30 -15:00 Member briefing seminar 'The Nagoya Protocol: will it impact your R&D and business development?' supported by the following panel:

  • Simon Trevenna, BEIS, and Thomas Murphy, Defra
  • Nigel Budgen, AZ
  • Rocky Cranenburgh, Prokarium

15:00 - 17:00 Meetings of the following BIA Advisory Committee

  • Engineering Biology
  • Genomics
  • Intellectual Property
  • Manufacturing
  • Regulatory Affairs

17:00 - 19:00    Drinks and networking 

Nagoya Protocol speakers
Nigel Budgen


Nigel Budgen, PhD, CSci. is a Product Stewardship Specialist in the Global Compliance function at the biopharmaceutical company AstraZeneca. Nigel has taken a leading role in the implementation of company policy and practises required to comply with the Nagoya protocol across the whole enterprise. Additionally, he specializes in sustainability assessments across the whole life cycle of products, from development to end of product life. Prior to working for AstraZeneca, he worked for Monsanto and Aspinwall as an Environmental Chemist. He graduated in Biochemistry from Bath University and is married with 2 children, and lives in rural Shropshire.

Rocky Cranenburgh


Rocky is the Chief Scientific Officer and co-founder of Prokarium Ltd, a UK-based biotechnology company specialising in the oral delivery of novel recombinant vaccines. Prokarium’s Vaxonella® platform uses attenuated Salmonella to express and deliver vaccines via the lining of the gastrointestinal tract. Rocky completed a Ph.D. in genomics of cyanobacteria at Newcastle University in 1997 and joined Cobra Biologics later that year. He spent two years from 1998 at the University of Oxford in a research collaboration, and then relocated to Cobra’s headquarters at Keele, Staffordshire in 2000. Rocky managed Cobra’s molecular biology group, which conducted numerous internal R&D projects and contracts for biopharmaceutical companies in the field of recombinant protein and DNA production. Rocky was involved in spinning Prokarium out from Cobra, and he has developed several new genetic technologies and vaccine candidates, and currently manages the development of vaccines for Chlamydia, C. difficile, plague and enteric fever.

Thomas Murphy


Graduate of Environmental Management (Land Use) at the University of Greenwich, Thomas worked for a number of years in the non-for-profit sector providing a range of expert services to help businesses and the public sector take action on energy efficiency and air quality.

Having moved into central government, Thomas has extensive experience in forming and delivering public policy both in the dynamic and challenging energy sector and now in the rewarding and exciting area of the Convention on Biological Diversity and Nagoya Protocol.

Thomas has briefed and accompanied ministers in debates in the UK, while at the international level Thomas forms part of the UK delegation negotiating on both the Convention of Biological Diversity and Nagoya at the highest levels.

Simon Trevenna


Group Manager: Heat, Timber, and Genetic Resources

After graduating in the Biological Sciences, Simon worked for several years as an Environmental Consultant and briefly as a Microbiologist. Experience includes assisting with international collections of biological samples and trade negotiation.

Now working at the Department for Business, Energy and Industrial Strategy (BEIS), Simon oversees implementation of several legislative areas throughout the UK, including the Nagoya Protocol on Access and Benefit Sharing (ABS).

During his five years as a Central Government Regulator, he has helped introduce and manage various environmentally linked regulations. A key focus has been to understand challenges faced by industry and international colleagues, developing efforts accordingly to effectively achieve desired outcomes whilst supporting business growth.



Kindly hosted by

BIA Annual Supporters